Skip to main content

Pentobarbital Dosage

Medically reviewed by Drugs.com. Last updated on Apr 9, 2024.

Applies to the following strengths: 50 mg/mL; 100 mg; 18.2 mg/5 mL; 120 mg; 60 mg; 50 mg; 200 mg; 30 mg; sodium

Usual Adult Dose for Insomnia

IM: 150 to 200 mg IM ONCE
IV:


Comments:

Uses:

Usual Adult Dose for Sedation

IM: 150 to 200 mg IM ONCE
IV:


Comments:

Uses:

Usual Adult Dose for Status Epilepticus

IM: 150 to 200 mg IM ONCE
IV:


Comments:

Uses:

Usual Pediatric Dose for Insomnia

Adequate, well-controlled studies have not been performed in pediatric patients; published case reports and other studies in pediatric patients supports safety and efficacy. Manufacturer suggested dosing:
IM: 2 to 6 mg/kg IM ONCE

IV: Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Comments:

Uses:

Usual Pediatric Dose for Sedation

Adequate, well-controlled studies have not been performed in pediatric patients; published case reports and other studies in pediatric patients supports safety and efficacy. Manufacturer suggested dosing:
IM: 2 to 6 mg/kg IM ONCE

IV: Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Comments:

Uses:

Usual Pediatric Dose for Status Epilepticus

Adequate, well-controlled studies have not been performed in pediatric patients; published case reports and other studies in pediatric patients supports safety and efficacy. Manufacturer suggested dosing:
IM: 2 to 6 mg/kg IM ONCE

IV: Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Comments:

Uses:

Renal Dose Adjustments

Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Liver Dose Adjustments

Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Dose Adjustments

Patients who are elderly and/or debilitated: The dose should be reduced because these patients may be more sensitive to barbiturates.

Withdrawal regimens: Cautious and gradual withdrawal of this drug should be performed over an extended period. The manufacturer product information should be consulted regarding recommendations for specific dosing regimens.

Precautions

CONTRAINDICATIONS:


Safety and efficacy of this drug have not been established in pediatric patients.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule II

Dialysis

Data not available

Other Comments

Administration advice:


IV compatibility:

General:

Monitoring:

Patient advice:
for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Patients should report any behavior of concern to their healthcare provider as soon as possible.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.